Skip to main content

Security report for angelinipharma.cz

Angelini Pharma Česká republika s.r.o. · Healthcare · Czech Republic

Low risk. 2 critical or high findings in GDPR outside view and SSL/TLS.

Security score

82/100

Risk levelLow

0–100, higher is better. How it is calculated

Angelini Pharma Česká republika s.r.o. is a medium-sized pharmaceutical company focused on the central nervous system (CNS), pain management, rare diseases, and consumer health products within the Czech Republic. It operates as a subsidiary of Angelini S.p.a., a larger parent company. The website presents a professional and consistent brand image, with comprehensive content targeting healthcare professionals and consumers. The company emphasizes research, development, manufacturing, and distribution of pharmaceutical products, positioning itself as a leading player in its sectors locally. Technically, the website employs modern JavaScript libraries such as jQuery, Slick Carousel, and Piwik PRO analytics, indicating a mature digital infrastructure. The site is mobile-optimized with good SEO practices and a cookie consent mechanism, reflecting compliance with privacy regulations. However, some security best practices like security headers and explicit incident response policies are not evident. From a security perspective, the site uses HTTPS and a consent management platform, but lacks visible security headers and explicit vulnerability disclosure mechanisms. The absence of WHOIS data reduces domain trustworthiness slightly, though the website content and certifications support legitimacy. No critical vulnerabilities or adult content were detected, and the site is fully accessible without WAF blocking. Overall, the website demonstrates a solid business and technical foundation with room for improvement in security transparency and WHOIS data availability. Strategic recommendations include enhancing security headers, publishing incident response information, and verifying domain registration details to strengthen trust and compliance.

Scanned

NIS2 and GDPR posture

GDPR outside view
73/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching angelinipharma.cz

This scan found 15 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
82
Security headers
90
Email security
70
DNS health
75
Network security
100
GDPR outside view
73
Average
82

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Angelini Pharma operates in the pharmaceutical healthcare sector with a focus on CNS, pain, rare diseases, and consumer health. The company leverages a research-driven business model with partnerships and subsidiaries across multiple European countries and the USA. Its competitive advantage lies in its dynamic R&D pipeline and strong manufacturing capabilities. The target customers include healthcare professionals and patients requiring specialized pharmaceutical products. The company shows growth through international subsidiaries and maintains a reputable brand with certifications like Top Employer Europe 2025. The website's multilingual and multi-regional presence supports a broad market reach. Strategic partnerships and collaborations in research further enhance its innovation capacity.

Security posture

The website exhibits a moderate to good security posture with HTTPS enforced and a cookie consent mechanism in place, indicating GDPR compliance. However, the absence of security headers such as Content Security Policy (CSP), HSTS, and X-Frame-Options suggests potential areas for improvement. No exposed sensitive data or vulnerable libraries were detected in the HTML content. The lack of explicit incident response and security policy pages limits transparency and readiness perception. No security.txt or vulnerability disclosure mechanisms were found, which could hinder responsible vulnerability reporting. Overall, the security maturity is adequate for the business type but could benefit from enhanced security controls and documentation.

Recommendations

  1. Implement comprehensive security headers including CSP, HSTS, X-Frame-Options, and X-XSS-Protection to strengthen defense against common web attacks.
  2. Publish explicit security policy and incident response information on the website to improve transparency and preparedness.
  3. Establish and publicize a vulnerability disclosure program, including a security.txt file, to facilitate responsible reporting and remediation.
  4. Verify and update WHOIS domain registration information to improve trust and legitimacy perception.
  5. Enhance accessibility features to meet higher compliance standards and improve user experience for all visitors.

Contact details published on the site

Addresses
Legal name
Angelini Pharma Česká republika s.r.o.
VAT number
CZ18824706
Registration number
Spisová značka: OR, Oddíl C vložka 1132, vedena u Krajského soudu v Brně
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Angelini Pharma Česká republika s.r.o.
Description
Angelini Pharma se zaměřuje na oblasti centrálního nervového systému (CNS), včetně bolesti a vzácných onemocnění. Společnost je také předním hráčem v sektoru Consumer Health.
Key services
Pharmaceutical research and development, Manufacturing of medicinal products, Consumer health products
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.7.1, jQuery Validation, Slick Carousel, Magnific Popup, Piwik PRO Analytics, Flip.js
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Piwik PRO
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Piwik PRO
Marketing tools
Piwik PRO Consent Manager
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content in Czech language.
  2. No WAF or security blocking detected.
  3. WHOIS data unavailable, possibly due to privacy protection or registry restrictions.
  4. Strong presence of privacy and cookie policies with consent management.
  5. Use of modern JavaScript libraries and analytics tools.
  6. No contact emails or phone numbers explicitly found in visible content.
  7. Physical address and company registration details clearly displayed in footer.
  8. Social media links to LinkedIn, Instagram, and Twitter present.
  9. No security.txt or explicit vulnerability disclosure found.
  10. No incident response or security policy pages detected.
Technical notes

Notes

The website uses a modern technology stack with jQuery 3.7.1, Slick Carousel for sliders, Magnific Popup for modals, and Piwik PRO for analytics and consent management. The site loads asynchronously loaded scripts and fonts from dedicated Angelini domains and Google Cloud Storage, indicating a well-structured content delivery approach. Performance is moderate with good mobile optimization and SEO meta tags. No CMS was explicitly detected, suggesting a custom or proprietary platform. The site lacks visible security headers and some accessibility features, which are technical debt areas. Hosting provider details are not disclosed in the HTML content. Overall, the technical implementation is solid with opportunities for security and accessibility enhancements.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with angelinipharma.cz. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review angelinipharma.cz.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.